Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687057 | 1.00 | HDAC1 (0.39) | HDAC1HDAC8HDAC6MKNK1P2RX7 | |
| SCHEMBL20528242 | 1.00 | HDAC1 (0.39) | HDAC1HDAC8HDAC6MKNK1P2RX7 | |
| SCHEMBL20528265 | 0.88 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL20528263 | 0.88 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL29686617 | 0.88 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL31165435 | 0.82 | CCR1 (0.44) | HDAC1HDAC8HDAC6MKNK1P2RX7 | |
| SCHEMBL29686639 | 0.81 | HDAC1 (0.36) | HDAC1HDAC8HDAC6P2RX7 | |
| SCHEMBL20528180 | 0.81 | HDAC1 (0.36) | HDAC1HDAC8HDAC6P2RX7 | |
| SCHEMBL20528179 | 0.81 | HDAC1 (0.36) | HDAC1HDAC8HDAC6P2RX7 | |
| SCHEMBL20528241 | 0.80 | PARP1 (0.39) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288931-B2 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| CN-107849012-B | Kinase inhibitor | 重庆复创医药研究有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | FOCHON BIOSCIENCES, LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450316-B2 | Certain protein kinase inhibitor | CDK4, CDK6, CDK2 | HDAC1 983/4885HDAC8 939/4885HDAC6 2579/4885 |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | CDK4, CDK6, CDK2 | HDAC1 938/4885HDAC8 648/4885HDAC6 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.